RXRX vs SRPT Stock Comparison
Compare RXRX and SRPT across AIQ Score, fundamentals, valuation, momentum, risk, analyst expectations and current market evidence.
What is the main difference between RXRX and SRPT?
SRPT leads the current stock comparison as Sarepta Therapeutics, Inc., with the clearest separation coming from value and the broader AIQ evidence mix.
AlgovestIQ AIQ Comparison
Recursion Pharmaceuticals, Inc. vs Sarepta Therapeutics, Inc.
SRPT leads
SRPT leads by 18 AIQ points, primarily on Value and Momentum, and the lead has widened from 14 points over 30 sessions. Wall Street currently favors RXRX on target upside.
Competitive: 4 of 6 evidence groups support SRPT, its lead is widening, and its current signal state is conflicted.
Recursion Pharmaceuticals, Inc.
Sarepta Therapeutics, Inc.
The Algovestiq AIQ Score currently favors SRPT over RXRX, 55 versus 37 as of Sep 11, 2026. SRPT's advantage is driven primarily by stronger value and momentum, while RXRX holds the stronger risk resilience profile. SRPT also shows the stronger technical structure relative to its 50-day moving average, though analyst target upside currently favors RXRX. 4 of 6 covered evidence groups favor SRPT today, and the comparison is rated Competitive on stability: the leader is throwing conflicting signals. SRPT lead: Strengthening — the AIQ differential moved from 14 to 18 points over 30 sessions.
Compare Recursion Pharmaceuticals, Inc. and Sarepta Therapeutics, Inc. across the Algovestiq AIQ Score, valuation, quality, momentum, risk, technicals and analyst expectations.
Performance over time
Price-return comparison using available daily close history.
Total return comparison
Growth of $10,000
Based on available close-price history. Distribution reinvestment is not added unless already reflected in the source series.
Compare RXRX and SRPT against another ticker
Open a multi-ticker workspace without changing this focused pair page.
AIQ Factor Divergence
Where the two separate, on the four dimensions behind the AIQ Score. Bars read outward from a shared zero: further from the centre is a wider gap.
- Value34 vs 64SRPT +30
- Momentum38 vs 66SRPT +28
- Risk Resilience58 vs 38RXRX +20
- Quality29 vs 46SRPT +17
4 of 6 evidence groups favor SRPT. SRPT’s edge is concentrated in value and momentum; RXRX keeps a meaningful risk resilience edge.
What changed since the last close
Latest scored session 2026-09-10, compared against the prior scored session 2026-09-09.
Largest factor move: Momentum +2
No new signals fired.
Largest factor move: Momentum -5
No new signals fired.
SRPT's lead narrowed by 1 AIQ points in the latest snapshot.
Deeper signal detail for each name lives on its own signals page — RXRX and SRPT both carry a full feed there.
The central trade-off
SRPT (Sarepta Therapeutics, Inc.): the stronger current systematic profile, led by value and momentum.
RXRX (Recursion Pharmaceuticals, Inc.): the counter-case, on risk resilience, analyst expectations.
The AIQ Score and Wall Street therefore point in different directions on this pair.
Which one fits your objective
The same two names rank differently depending on what you are optimizing for. All six reads are shown at once — none of them is hidden behind a toggle.
Balanced
SRPTSRPT on the overall AIQ Score, which weights Quality and Value most heavily.
Growth
RXRXRXRX on combined revenue and EPS growth.
Value
SRPTSRPT on the peer-relative Value factor, by 30 points.
Momentum
SRPTSRPT on the Momentum factor, by 28 points.
Lower downside
RXRXRXRX on Risk Resilience, by 20 points.
Analyst upside
RXRXRXRX on implied upside to the consensus price target.
AIQ vs Wall Street
The model and the Street disagree here: AIQ favors SRPT, analyst targets favor RXRX. That disagreement is the most useful thing on this page.
| Measure | RXRX | SRPT | Note |
|---|---|---|---|
| Implied upside to target | +68.8% | +14.1% | RXRX has more room |
| Target dispersion | +3.7% | +90% | Lower is tighter analyst agreement |
| Consensus | Buy | Hold | Context, not a primary driver |
| Analysts covering | 1 | 6 | Higher coverage generally improves confidence |
The two are measuring different things. The AIQ Score reads current fundamentals, valuation, trend and risk; analyst targets price forward expectations. A divergence of this kind is either a contrarian opportunity or a sign the model is missing something already priced in — it is worth resolving before acting on either.
Analyst targets are expectations, not predictions. Dispersion matters as much as the midpoint.
AIQ Agreement Matrix
4 of 6 covered evidence groups favor SRPT. A wide gap backed by one group is a weaker case than a narrow gap backed by five.
| Evidence group | Favors | Reading |
|---|---|---|
| AIQ Score | SRPT | 37 vs 55 |
| Fundamentals | SRPTon balance | revenue growth 18.5% vs -45.1%; EPS growth -13.6% vs -101.6%; TTM ROE -50.4% vs -10%; gross margin -46.7% vs 58.6%; operating margin -9.9% vs -7.3% — SRPT takes 3 of 5 decided legs, not all of them |
| Valuation | SRPT | Value 34 vs 64 |
| Technicals | SRPT | Price vs 50-day -3.2% vs 10.9%; vs 200-day -13.1% vs 6.6% |
| Risk Resilience | RXRX | Risk Resilience 58 vs 38 |
| Analyst expectations | RXRX | Target upside 68.8% vs 14.1% |
✓ agrees with the overall verdict · ✕ points the other way. Groups marked “not covered” lack data on one or both of RXRX and SRPT and are excluded from the count.
AIQ Decision Stability
The two are close enough that your objective, not the score, should decide.
- The AIQ gap is wide at 18 points. (supports the conclusion holding)
- The leader's advantage has been widening. (supports the conclusion holding)
- The lead has been steady session to session. (supports the conclusion holding)
- The leader is throwing conflicting signals. (argues the conclusion is provisional)
- Analyst targets on the leader are widely dispersed. (argues the conclusion is provisional)
Stability combines the score gap, how broadly the evidence agrees, how steady the lead has been across daily snapshots, the current signal state on both names, and analyst dispersion on SRPT.
How the comparison changed
119 daily snapshots · May 4 – Sep 10SRPT lead: Strengthening — the AIQ differential moved from 14 to 18 points over 30 sessions.
- Today
- SRPT +18
- 37 vs 55
- 7 sessions ago
- SRPT +14
- 44 vs 58
- 30 sessions ago
- SRPT +14
- 45 vs 59
- 90 sessions ago
- SRPT +13
- 46 vs 59
The lead has not changed hands in this window.
AIQ Signal Divergence
Only the signals that bear on the head-to-head. A conflicted name is carrying bullish and bearish rules at the same time — the technical evidence is not pointing one way.
0 bullish / 3 bearish / 1 neutral
- Death Cross Active — bearish, trend, long horizon (9.97%)
- Downtrend Structure Active — bearish, trend, long horizon
- ATR Expansion - Breakout Mode — neutral, volatility, short horizon (6.16%)
2 bullish / 1 bearish / 2 neutral, conflicted
- Death Cross Active — bearish, trend, long horizon (4.35%)
- Bollinger Band Squeeze — neutral, volatility, short horizon
- EMA Ribbon Expansion Bullish — bullish, trend, medium horizon
SRPT leads the comparison while carrying a conflicted signal state, which is one reason the stability rating is not higher.
Price vs model alignment
Whether the latest session's price move confirms what the model did over the same session, or contradicts it.
Neither the price nor the AIQ Score moved enough in the latest session to confirm or contradict the other (price +1.27%, AIQ 0 points).
Price and the AIQ Score both moved down over the latest session (price -0.34%, AIQ -1 points).
What would flip this result
A state, not a forecast. These are the specific, observable changes that would reverse the verdict — not a price prediction.
- 1RXRX closes the Value gap — currently 30 points behind, the largest single contributor to SRPT's edge.
- 2RXRX's Death Cross Active resolves — a bearish trend rule currently active against it.
- 3SRPT's conflicting signal state resolves bearish — it currently carries 2 bullish and 1 bearish rules at once.
- 4A regime shift changes factor weighting — Quality and Value carry the heaviest weights in the composite, so a rotation toward either would move the result most.
The full evidence
Every number behind the verdict. The leader is called above each group so you are not left to solve it from the table.
Fundamentals
SRPT leads on balance| Metric | RXRX | SRPT |
|---|---|---|
| Revenue growth (YoY) | 18.5% | -45.1% |
| EPS growth (YoY) | -13.6% | -101.6% |
| Gross margin | -46.7% | 58.6% |
| Operating margin | -9.9% | -7.3% |
| Return on equity (TTM) | -50.4% | -10% |
| Debt to equity | 0.07 | 0.68 |
Performance
SRPT leads 5 of 6 windows| Metric | RXRX | SRPT |
|---|---|---|
| 1 week (5 sessions) | -6.5% | -11.6% |
| 1 month (20 sessions) | -4% | 11.6% |
| 3 months (63 sessions) | 3.9% | 35.8% |
| 6 months (126 sessions) | -8.4% | 16.8% |
| Year to date | -22.7% | -4.6% |
| 1 year (252 sessions) | -31.6% | 16.6% |
Technicals
SRPT has the stronger structure| Metric | RXRX | SRPT |
|---|---|---|
| RSI (14) | 45.1 | 55.2 |
| ADX (14) | 12.8 | 32 |
| Price vs 50-day | -3.2% | 10.9% |
| Price vs 200-day | -13.1% | 6.6% |
| Volatility (1M, annualized) | 82.8% | 79.3% |
Risk
RXRX is the more resilient| Metric | RXRX | SRPT |
|---|---|---|
| Beta | 2.88 | 2.1 |
| Sharpe ratio | -0.26 | 0.55 |
| Sortino ratio | -0.5 | 0.76 |
| Max drawdown | -58.2% | -39.2% |
| Current drawdown | -53.5% | -16.1% |
| Annualized volatility | 71.8% | 81.3% |
| Value at risk (95%) | -6.6% | -6.6% |
Straight answers
Each answer is regenerated from the current snapshot, not written once and left to age.
Which is better, RXRX or SRPT?
On the Algovestiq AIQ Score, SRPT is the stronger of the two as of Sep 11, 2026, scoring 55 against RXRX's 37. The edge comes from value and momentum. RXRX is not without a case — it holds the better risk resilience profile, which matters more if that is the objective you are optimizing for. This is a systematic score, not a recommendation: it ranks the two on the same evidence, it does not know your holding period or tax position.
Is RXRX or SRPT the better buy right now?
SRPT carries the stronger systematic profile as of Sep 11, 2026, and the comparison is rated Competitive — 4 of 6 covered evidence groups agree. A Competitive rating means the two are close enough that your objective, not the score, should decide.
Why does the AIQ Score favor SRPT over RXRX?
The composite weights Quality, Value, Momentum and Risk Resilience. SRPT leads Value by 30 points; SRPT leads Momentum by 28 points; RXRX leads Risk Resilience by 20 points. Where the two split, the factor with the larger weight carries the result.
Which has more analyst upside, RXRX or SRPT?
Analyst price targets imply +68.8% upside for RXRX and +14.1% for SRPT, so the Street currently favors RXRX. That points the opposite way to the AIQ Score, which favors SRPT. The two are measuring different things: the model reads current fundamentals, valuation, trend and risk; the Street is pricing forward expectations. A divergence of this kind is either a contrarian opportunity or a sign the model is missing something the analysts have already priced — it is the single most useful row on this page to investigate. Analyst targets are expectations, not predictions, and dispersion matters as much as the midpoint.
Which is better value, RXRX or SRPT?
SRPT is the better-valued of the two on the peer-relative Value factor. SRPT on the peer-relative Value factor, by 30 points. The Value factor reads valuation relative to sector peers and to the company's own fundamental quality, so it is not the same as simply having the lower multiple.
Which has stronger growth, RXRX or SRPT?
RXRX on combined revenue and EPS growth. Growth here is measured on reported revenue and earnings, not on forward estimates — it describes what the businesses have delivered, not what the Street expects next.
Which has stronger momentum, RXRX or SRPT?
SRPT on the Momentum factor, by 28 points. Momentum is one of the four weighted factors in the AIQ composite. It has documented persistence over three- to twelve-month horizons, which makes it a timing input rather than a reason to hold something indefinitely.
Which is riskier, RXRX or SRPT?
RXRX is the more resilient of the two, so the other name carries the higher downside risk. RXRX on Risk Resilience, by 20 points. Risk Resilience is a weighted factor in the composite; position sizing usually responds to it more usefully than the buy/avoid decision does.
Is RXRX more profitable than SRPT?
SRPT leads on the comparable margin measures — gross margin -46.7% vs 58.6%; operating margin -9.9% vs -7.3%; ttm roe -50.4% vs -10%.
Is SRPT's lead over RXRX getting stronger or weaker?
SRPT lead: Strengthening — the AIQ differential moved from 14 to 18 points over 30 sessions. This is measured from 119 daily comparison snapshots between 2026-05-04 and 2026-09-10. The lead has not changed hands in that window.
What would change the RXRX vs SRPT verdict?
The result is a state, not a forecast, so it changes when the underlying evidence changes. Concretely: RXRX closes the Value gap — currently 30 points behind, the largest single contributor to SRPT's edge; RXRX's Death Cross Active resolves — a bearish trend rule currently active against it; SRPT's conflicting signal state resolves bearish — it currently carries 2 bullish and 1 bearish rules at once; a regime shift changes factor weighting — Quality and Value carry the heaviest weights in the composite, so a rotation toward either would move the result most.
What do the current signals say about RXRX and SRPT?
RXRX: 0 bullish / 3 bearish / 1 neutral. SRPT: 2 bullish / 1 bearish / 2 neutral, conflicted. A conflicted state means bullish and bearish rules are active on the same name at once — the technical evidence is not pointing one way, and a decision taken on it carries more timing risk. The most decision-relevant rule on RXRX is Death Cross Active (bearish, long horizon). On SRPT it is Death Cross Active (bearish, long horizon).
Compare RXRX and SRPT with others
Continue your research
This page answers which of the two. These answer the questions on either side of it.
How this comparison is scored
The Algovestiq AIQ Score composites four factors — Quality, Value, Momentum and Risk, each carrying a fixed weight. Sentiment is reported separately as SentimentPulse and is not folded into the composite. Scores refresh every trading day, and this page regenerates from the latest snapshot rather than being written once.
The verdict names a leader, states how broadly six independent evidence groups agree, and rates how durable that conclusion is given the score gap, its recent trajectory and the current signal state on both names.
How to use side-by-side comparison →This comparison is informational and educational, not investment advice. AIQ scores update daily; re-check after earnings, guidance or macro data that materially changes either name’s factor profile.